Clinical Trial Update: A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

Pfizer-sponsored Phase 1 trial of an intravenously administered cyclin-dependent kinase inhibitor in patients with advanced cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Snippet

Sponsor: Pfizer | Conditions: Neoplasms, Lymphoma, Non-Hodgkin | Phase 1 | Status: TERMINATED